Romanian journal of internal medicine = Revue roumaine de medecine interne · 2026
Real-World Effectiveness of Biologic Therapy in Patients with Psoriasis: Metabolic Comorbidities and Treatment Outcomes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghilencea Adelina F, Costache Daniel O, Căruntu Constantin, Scheau Cristian, Savulescu-Fiedler Ilinca, Dicu-Andreescu Ioana, Cojocaru Damian, Costache Raluca S
Аннотация
INTRODUCTION: Psoriasis is a chronic systemic inflammatory disease, frequently associated with metabolic comorbidities that may influence therapeutic outcomes. Real-world evidence on the effectiveness of biologic therapy in this complex clinical context remains limited.
OBJECTIVES: To assess the prevalence of comorbidities in patients with psoriasis receiving biologic therapy and to identify factors associated with treatment response.
METHODS: A retrospective observational study including 121 patients with chronic plaque psoriasis. Demographic data, comorbidities, biologic treatment class, and PASI/DLQI evolution at baseline and at standardized 6 and 12 months assessments was analyzed, together with the latest available clinical assessment recorded in 2025 after variable treatment durations.
RESULTS: Comorbidities were present in 84.3% of patients, most frequently hepatic steatosis (73.6%), obesity (45.5%), hypertension (41.3%), and diabetes (19%). A significant improvement in PASI and DLQI scores was observed at all follow-up points (p < 0.001). Complete skin clearance (PASI 100) was achieved by 18.1% of the patients at 6 months and by 44.6% at 12 months. In multivariable logistic regression analysis, lower PASI scores at six months were independently associated with a higher likelihood of achieving PASI 100 at one year.
CONCLUSIONS: Biologic therapy was associated with marked clinical and quality-of-life improvement. Although metabolic comorbidities were highly prevalent, no significant association between metabolic comorbidities and PASI 100 response at one year was identified in the analyses performed.
OBJECTIVES: To assess the prevalence of comorbidities in patients with psoriasis receiving biologic therapy and to identify factors associated with treatment response.
METHODS: A retrospective observational study including 121 patients with chronic plaque psoriasis. Demographic data, comorbidities, biologic treatment class, and PASI/DLQI evolution at baseline and at standardized 6 and 12 months assessments was analyzed, together with the latest available clinical assessment recorded in 2025 after variable treatment durations.
RESULTS: Comorbidities were present in 84.3% of patients, most frequently hepatic steatosis (73.6%), obesity (45.5%), hypertension (41.3%), and diabetes (19%). A significant improvement in PASI and DLQI scores was observed at all follow-up points (p < 0.001). Complete skin clearance (PASI 100) was achieved by 18.1% of the patients at 6 months and by 44.6% at 12 months. In multivariable logistic regression analysis, lower PASI scores at six months were independently associated with a higher likelihood of achieving PASI 100 at one year.
CONCLUSIONS: Biologic therapy was associated with marked clinical and quality-of-life improvement. Although metabolic comorbidities were highly prevalent, no significant association between metabolic comorbidities and PASI 100 response at one year was identified in the analyses performed.